From: Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximab
Whole group (n = 46)
BRAFV600E
Mut
2 (4%)
Wild Type
44 (96%)
PIK3CA exon 20
3 (6%)
43 (94%)
EGFR FISH GCN
<2.6
18 (39%)
≥2.6
28 (61%)
HER 3 IHC Score
>8
20 (44%)
≤8
26 (56%)
IGF-1 IHC Score
≥2
16 (35%)
<2
30 (65%)